219,528 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Acquired by Norges Bank

Norges Bank purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 219,528 shares of the company's stock, valued at approximately $34,391,000. Norges Bank owned 0.76% of Krystal Biotech at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech during the third quarter valued at approximately $40,000. Avanza Fonder AB bought a new position in shares of Krystal Biotech during the 4th quarter valued at $119,000. KBC Group NV raised its holdings in shares of Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after purchasing an additional 297 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares in the last quarter. Finally, US Bancorp DE raised its holdings in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after acquiring an additional 82 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Down 4.0 %

Krystal Biotech stock traded down $6.65 during mid-day trading on Thursday, hitting $161.51. 37,134 shares of the stock were exchanged, compared to its average volume of 279,080. The firm's fifty day simple moving average is $173.85 and its two-hundred day simple moving average is $172.48. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34. The stock has a market capitalization of $4.65 billion, a price-to-earnings ratio of 54.02 and a beta of 0.75.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. During the same period in the previous year, the business posted $0.30 EPS. The firm's quarterly revenue was up 116.4% compared to the same quarter last year. As a group, analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup raised their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Friday, February 28th. Finally, Chardan Capital boosted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $220.00.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).